The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

20 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.EBI
Stony Brook University
Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A.EBI
Stony Brook University
New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase.EBI
Stony Brook University
Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus.EBI
Stony Brook University
Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR ligands.EBI
Stony Brook University
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.EBI
Stony Brook University
Inhibition of the M. tuberculosis 3β-hydroxysteroid dehydrogenase by azasteroids.EBI
Stony Brook University
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.EBI
Stony Brook University
Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13.EBI
Stony Brook University
Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.EBI
Stony Brook University
Truxillic acid monoamides as fatty acid binding protein 5 inhibitors.EBI
Stony Brook University
Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.EBI
Stony Brook University
Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy.EBI
Stony Brook University
Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarity.EBI
Stony Brook University
New Frontiers in Druggability.EBI
Stony Brook University
SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.EBI
Stony Brook University
4-piperidinyl compounds for use as tankyrase inhibitorsBDB
Novartis
Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRKBDB
Medical Research Council Technology
New, potent P1/P2-morpholinone-based HIV-protease inhibitors.BDB
Glaxosmithkline